Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2013 | Original Article

⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma

Authors: Volker H. Schartinger, József Dudás, Clemens Decristoforo, Christoph Url, Johannes Schnabl, Georg Göbel, Irene J. Virgolini, Herbert Riechelmann, Michael Rasse, Dietmar Waitz, Daniel Putzer

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2013

Abstract

Purpose

⁶⁸Ga-labelled DOTA⁰-Tyr³-octreotide positron emission tomography (PET)/CT (⁶⁸Ga-DOTATOC PET/CT) is a routinely used imaging modality for neuroendocrine tumours expressing somatostatin receptors (SSTRs). Recent studies have shown that SSTRs are also expressed in head and neck squamous cell carcinoma (HNSCC). This is the first prospective clinical trial investigating SSTR expression in patients with HNSCC using ⁶⁸Ga-DOTATOC.

Methods

Patients with previously untreated HNSCC underwent ⁶⁸Ga-DOTATOC PET/CT (120 MBq, range 81–150 MBq). Tumour tracer uptake was scored, the maximum standardized uptake value (SUV_max) was measured and the tumour to background uptake ratio was calculated. For each patient, PET/CT findings were correlated with immunohistochemical SSTR expression in tumour specimens.

Results

Fifteen HNSCC patients were included in the study from May 2011 to May 2012. Tumour-specific ⁶⁸Ga-DOTATOC uptake was detected in all patients with an median SUV_max of 4.0 (range 2.2–6.5). Uptake was weak in seven (47 %), moderate in five (33 %) and strong in three (20 %) patients. All tumour specimens were SSTR positive on immunohistochemistry. Of the 15 patients, 14 were positive for SSTR subtype 2, characterized by the highest affinity to octreotide.

Conclusion

SSTR expression in HNSCC can be visualized clinically using ⁶⁸Ga-DOTATOC PET/CT. SSTR expression in HNSCC could provide a potential target for SSTR-based therapy in patients not amenable to standard treatment modalities, but this cannot be predicted by SSTR immunohistochemistry.

Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77–9.PubMedCrossRef

Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008;15:701–20.PubMedCrossRef

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.PubMedCrossRef

Reubi JC. Clinical relevance of somatostatin receptor imaging. Eur J Endocrinol 1994;131:575–6.PubMedCrossRef

Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742–53.PubMedCrossRef

Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010;54:3–15.PubMed

Nisman B, Heching N, Biran H, Barak V, Peretz T. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour Biol 2006;27:8–16.PubMedCrossRef

Yuan A, Liu J, Liu Y, Cui G. Chromogranin A-positive tumor cells in human esophageal squamous cell carcinomas. Pathol Oncol Res 2007;13:321–5.PubMedCrossRef

Stafford ND, Condon LT, Rogers MJ, MacDonald AW, Atkin SL. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clin Otolaryngol Allied Sci 2003;28:314–9.PubMedCrossRef

10.

Condon LT, Stafford ND, Bedford KJ, MacDonald AW, Atkin SL. The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. Eur Arch Otorhinolaryngol 2008;265 Suppl 1:S63–7.PubMedCrossRef

11.

Schartinger VH, Falkeis C, Laimer K, Sprinzl GM, Riechelmann H, Rasse M, et al. Neuroendocrine differentiation in head and neck squamous cell carcinoma. J Laryngol Otol 2012;126:1261–70.

12.

Ambrosini V, Campana D, Tomassetti P, Grassetto G, Rubello D, Fanti S. PET/CT with 68Gallium-DOTA-peptides in NET: an overview. Eur J Radiol 2011;80:e116–9.PubMedCrossRef

13.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.PubMedCrossRef

14.

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36:48–52.PubMedCrossRef

15.

Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870–5.PubMedCrossRef

16.

Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 1994;55:1797–806.PubMedCrossRef

17.

Sagman U, Mullen JB, Kovacs K, Kerbel R, Ginsberg R, Reubi JC. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer 1990;66:2129–33.PubMedCrossRef

18.

Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun 2004;25:445–9.PubMedCrossRef

19.

Culler MD, Öberg K, Arnold R, Krenning EP, Sevilla I, Díaz JA. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011;30 Suppl 1:9–17.PubMedCrossRef

20.

Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009;25:2989–99.PubMedCrossRefPubMedCentral

21.

Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 2006;17:601–8.PubMedCrossRef

22.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31.PubMed

23.

Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010;54:92–9.PubMed

24.

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004–10.PubMedCrossRef

25.

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011;18 Suppl 1:S27–51.PubMedCrossRef

26.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef

27.

Gilon C, Huenges M, Mathä B, Gellerman G, Hornik V, Afargan M, et al. A backbone-cyclic, receptor 5-selective somatostatin analogue: synthesis, bioactivity, and nuclear magnetic resonance conformational analysis. J Med Chem 1998;41:919–29.PubMedCrossRef

28.

Kvols LK, Oberg KE, O’Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 2012;19:657–66.PubMedCrossRef

Title: 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma
Authors: Volker H. Schartinger
József Dudás
Clemens Decristoforo
Christoph Url
Johannes Schnabl
Georg Göbel
Irene J. Virgolini
Herbert Riechelmann
Michael Rasse
Dietmar Waitz
Daniel Putzer
Publication date: 01-09-2013
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2442-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2013

Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CT

High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma

Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer

PET/CT and breast cancer subtypes

Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma